MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: hepatocellular carcinoma
MedXY News
EnglishTag

hepatocellular carcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
newshepatocellular carcinomaimmunotherapy

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

By MedXY|Nov 30, 2025

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combinati

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
Gastroenterologygraft rejectionhepatocellular carcinoma

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

By MedXY|Nov 6, 2025

A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma
newscamrelizumabEvent-free survival

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

In the phase 3 CARES-009 trial, perioperative camrelizumab combined with rivoceranib significantly improved event-free survival and major pathological response in patients with resectable high-risk hepatocellular carcinoma, compared to surg

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma
newsatezolizumabbevacizumab

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.

Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma
Gastroenterologyhepatocellular carcinoma

Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma

By MedXY|Oct 28, 2025

A phase I trial reveals that ADP-A2AFP TCR T-cell therapy, targeting AFP-expressing advanced hepatocellular carcinoma and gastric hepatoid carcinoma, is safe and exhibits early antitumor activity in patients refractory to conventional treat

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers
newshepatocellular carcinomaimmunotherapy

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY|Oct 28, 2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy
newsclinical trialshepatocellular carcinoma

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

By MedXY|Oct 28, 2025

Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial
newsatezolizumabbevacizumab

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

By MedXY|Oct 28, 2025

A recent phase II trial demonstrates lenvatinib’s efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming
newsAlcoholHBV

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY|Oct 27, 2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma
Gastroenterologygut microbiotahepatocellular carcinoma

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma

By MedXY|Oct 27, 2025

This review explores how gut microbiota disturbances, especially L. reuteri and its metabolite ILA, influence post-TACE liver injury and prognosis in HCC patients, highlighting potential microbiota-targeted therapies.

Comparative Risks of MASLD and MetALD: Insights from a Comprehensive Meta-Analysis on Hepatic and Extrahepatic Outcomes
Gastroenterologyhepatocellular carcinomaliver-related events

Comparative Risks of MASLD and MetALD: Insights from a Comprehensive Meta-Analysis on Hepatic and Extrahepatic Outcomes

By MedXY|Oct 19, 2025

This meta-analysis reveals that MetALD confers higher risks of liver-related events, hepatocellular carcinoma, and extrahepatic cancers compared to MASLD, while mortality and cardiovascular risks are similar, emphasizing tailored clinical a

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score
Gastroenterologyhepatocellular carcinomaMASLD

Risk Stratification of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic Dysfunction and MASLD: Validating the PAGE-B Score

By MedXY|Oct 9, 2025

Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful m

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes
Superintelligencehepatocellular carcinomaimmunotherapy

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

By MedXY|Sep 27, 2025

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy

Optimizing Treatment Selection for Hepatocellular Carcinoma: Machine Learning Guidance in Choosing Liver Transplantation versus Surgical Resection
General Surgeryhepatocellular carcinomaliver transplantation

Optimizing Treatment Selection for Hepatocellular Carcinoma: Machine Learning Guidance in Choosing Liver Transplantation versus Surgical Resection

By MedXY|Sep 23, 2025

A machine learning model accurately stratifies patients with hepatocellular carcinoma to guide individualized selection between liver transplantation and surgical resection, improving survival outcomes while addressing donor scarcity and pa

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma
Clinical UpdatesHBVhepatocellular carcinoma

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY|Sep 4, 2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatment

Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban
newsAtosibanhepatocellular carcinoma

Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban

By MedXY|Aug 31, 2025

Recent research identifies the oxytocin receptor (OXTR) as a critical driver of liver cancer via Hippo/YAP signaling. The FDA-approved tocolytic drug Atosiban shows promise in blocking this pathway, offering new therapeutic avenues in hepat

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials
Clinical Updatesclinical trialhepatocellular carcinoma

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY|Aug 7, 2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials
Clinical Updatesclinical trialhepatocellular carcinoma

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY|Aug 7, 2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial
Clinical Updatesbevacizumabhepatocellular carcinoma

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY|Aug 2, 2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.

Prev
3 / 3
123
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models